Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Accumulated Expenses data on file, last reported at $19.8 million in Q1 2026.

• Quarterly Accumulated Expenses rose 3.04% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (up 3.04% YoY) and the FY2025 annual result came in at $23.4 million, up 9.21% from the prior year.
• Accumulated Expenses retreated to $19.8 million in Q1 2026, from $23.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $23.4 million in Q4 2025 to a low of $14.6 million in Q1 2022.
• A 5-year average of $19.5 million and a median of $20.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 54.72% — and 2024, when it decreased 20.94%.
• Tracing CTKB's Accumulated Expenses over 5 years: stood at $21.1 million in 2022, then dropped by 5.16% to $20.0 million in 2023, then increased by 7.03% to $21.4 million in 2024, then grew by 9.21% to $23.4 million in 2025, then retreated by 15.53% to $19.8 million in 2026.
• The last three Accumulated Expenses figures came in at $19.8 million (Q1 2026), $23.4 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.